REGN
Price
$576.91
Change
+$9.02 (+1.59%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
60.19B
36 days until earnings call
SMMT
Price
$20.51
Change
+$1.36 (+7.10%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
14.23B
42 days until earnings call
Interact to see
Advertisement

REGN vs SMMT

Header iconREGN vs SMMT Comparison
Open Charts REGN vs SMMTBanner chart's image
Regeneron Pharmaceuticals
Price$576.91
Change+$9.02 (+1.59%)
Volume$9.3K
Capitalization60.19B
Summit Therapeutics
Price$20.51
Change+$1.36 (+7.10%)
Volume$122.87K
Capitalization14.23B
REGN vs SMMT Comparison Chart in %
Loading...
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SMMT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
REGN vs. SMMT commentary
Sep 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is REGN is a Buy and SMMT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 25, 2025
Stock price -- (REGN: $567.89 vs. SMMT: $19.15)
Brand notoriety: REGN: Notable vs. SMMT: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: REGN: 136% vs. SMMT: 81%
Market capitalization -- REGN: $60.19B vs. SMMT: $14.23B
REGN [@Biotechnology] is valued at $60.19B. SMMT’s [@Biotechnology] market capitalization is $14.23B. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

REGN’s FA Score shows that 1 FA rating(s) are green whileSMMT’s FA Score has 1 green FA rating(s).

  • REGN’s FA Score: 1 green, 4 red.
  • SMMT’s FA Score: 1 green, 4 red.
According to our system of comparison, REGN is a better buy in the long-term than SMMT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

REGN’s TA Score shows that 5 TA indicator(s) are bullish while SMMT’s TA Score has 5 bullish TA indicator(s).

  • REGN’s TA Score: 5 bullish, 3 bearish.
  • SMMT’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, REGN is a better buy in the short-term than SMMT.

Price Growth

REGN (@Biotechnology) experienced а -1.25% price change this week, while SMMT (@Biotechnology) price change was +5.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was +10.70%, and the average quarterly price growth was +54.52%.

Reported Earning Dates

REGN is expected to report earnings on Oct 30, 2025.

SMMT is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
REGN($60.2B) has a higher market cap than SMMT($14.2B). SMMT has higher P/E ratio than REGN: SMMT (26.41) vs REGN (14.31). SMMT YTD gains are higher at: 7.313 vs. REGN (-19.935). REGN has higher annual earnings (EBITDA): 5.42B vs. SMMT (-743.48M). REGN has more cash in the bank: 7.47B vs. SMMT (298M). SMMT has less debt than REGN: SMMT (5.55M) vs REGN (2.71B). REGN has higher revenues than SMMT: REGN (14.2B) vs SMMT (0).
REGNSMMTREGN / SMMT
Capitalization60.2B14.2B424%
EBITDA5.42B-743.48M-729%
Gain YTD-19.9357.313-273%
P/E Ratio14.3126.4154%
Revenue14.2B0-
Total Cash7.47B298M2,507%
Total Debt2.71B5.55M48,712%
FUNDAMENTALS RATINGS
REGN vs SMMT: Fundamental Ratings
REGN
SMMT
OUTLOOK RATING
1..100
56
VALUATION
overvalued / fair valued / undervalued
1..100
3
Undervalued
95
Overvalued
PROFIT vs RISK RATING
1..100
10052
SMR RATING
1..100
54100
PRICE GROWTH RATING
1..100
6187
P/E GROWTH RATING
1..100
958
SEASONALITY SCORE
1..100
4350

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

REGN's Valuation (3) in the Biotechnology industry is significantly better than the same rating for SMMT (95). This means that REGN’s stock grew significantly faster than SMMT’s over the last 12 months.

SMMT's Profit vs Risk Rating (52) in the Biotechnology industry is somewhat better than the same rating for REGN (100). This means that SMMT’s stock grew somewhat faster than REGN’s over the last 12 months.

REGN's SMR Rating (54) in the Biotechnology industry is somewhat better than the same rating for SMMT (100). This means that REGN’s stock grew somewhat faster than SMMT’s over the last 12 months.

REGN's Price Growth Rating (61) in the Biotechnology industry is in the same range as SMMT (87). This means that REGN’s stock grew similarly to SMMT’s over the last 12 months.

SMMT's P/E Growth Rating (8) in the Biotechnology industry is significantly better than the same rating for REGN (95). This means that SMMT’s stock grew significantly faster than REGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
REGNSMMT
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
73%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
55%
Bullish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
66%
Bullish Trend 2 days ago
89%
MACD
ODDS (%)
Bullish Trend 2 days ago
67%
N/A
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
57%
Bullish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
64%
Bearish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 7 days ago
63%
Bullish Trend 2 days ago
86%
Declines
ODDS (%)
Bearish Trend 16 days ago
53%
Bearish Trend 8 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
57%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
60%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
REGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SMMT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PSL108.640.03
+0.02%
Invesco DW Consumer Staples Momt ETF
BBAGF42.50N/A
N/A
BB Biotech AG
STEW18.18-0.06
-0.33%
SRH Total Return Fund
CSMD33.59-0.25
-0.74%
Congress SMid Growth ETF
QQQS32.65-0.25
-0.76%
Invesco NASDAQ Future Gen 200 ETF

REGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, REGN has been loosely correlated with BMRN. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then BMRN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REGN
1D Price
Change %
REGN100%
-4.67%
BMRN - REGN
44%
Loosely correlated
-0.98%
ROIV - REGN
42%
Loosely correlated
-1.34%
SMMT - REGN
41%
Loosely correlated
+0.26%
ACLX - REGN
40%
Loosely correlated
+1.19%
TECH - REGN
39%
Loosely correlated
-0.23%
More

SMMT and

Correlation & Price change

A.I.dvisor indicates that over the last year, SMMT has been closely correlated with BCDA. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if SMMT jumps, then BCDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SMMT
1D Price
Change %
SMMT100%
+0.26%
BCDA - SMMT
69%
Closely correlated
+27.03%
BNTX - SMMT
49%
Loosely correlated
-0.46%
TIL - SMMT
49%
Loosely correlated
-8.83%
IMNM - SMMT
43%
Loosely correlated
+8.09%
IDYA - SMMT
42%
Loosely correlated
+0.04%
More